User Information
NEWS | CME 
Women's heart attacks differ from men's   Non-HDL Cholesterol: When and how to Treat   Community-based lifestyle intervention beneficial in Chinese diabetes, hypertension patients   Asian lung cancer vaccine trial resumes after temporary hold   Coronary CT predicts future cardiac events   Conflicting Recommendations for Lipid Screening and Management in Children: The Need for Consensus   Researchers in Asia point to better sepsis treatments   Ethnicity is a strong indicator of cardiovascular risk   Type 1 Diabetes Mellitus in Children and Adolescents   Gefitinib improves progression-free survival in NSCLC with EGFR mutations   Chinese women largely unaware of heart disease and stroke risk   7th International Symposium on Respiratory Diseases (ISRD)   The JUPITER trial: Do the results apply to Asians?   Linagliptin lowers blood sugar in type 2 diabetics   Recommendations for the Management of Neuropathic Pain Associated With Peripheral Nerve Entrapment   
Essential Prescribing Information

Ciproxin® [infusion]

Bayer [ Hong Kong: Zuellig ]
MIMS Class : Quinolones
  
See related Ciproxin infusion information
Contents
Ciprofloxacin (Tab:HCl monohydrate; Inj:Lactate).
Indications
Listed in Dosage.
Dosage
Adult UTI, acute uncomplicated 100 or 250 mg orally 12 hrly for 3 days, mild/moderate 250 mg orally or 200 mg IV 12 hrly for 7-14 days, severe/complicated 500 mg orally or 400 mg IV 12 hrly for 7-14 days. Chronic bacterial prostatitis, mild/moderate 500 mg orally or 400 mg IV 12 hrly for 28 days. Lower resp tract infections, mild/moderate 500 mg orally or 400 mg IV 12 hrly for 7-14 days, severe/complicated 750 mg orally 12 hrly or 400 mg IV 8 hrly for 7-14 days. Nosocomial pneumonia, mild/moderate/severe 400 mg IV 8 hrly for 10-14 days. Acute sinusitis, mild/moderate 500 mg orally or 400 mg IV 12 hrly for 10 days. Skin & skin structure, mild/moderate 500 mg orally or 400 mg IV 12 hrly for 7-14 days, severe/complicated 750 mg orally 12 hrly or 400 mg IV 8 hrly for 7-14 days. Bone & joint infections, mild/moderate 500 mg orally or 400 mg IV 12 hrly for ≥4-6 weeks, severe/complicated 750 mg 12 hrly orally or 400 mg IV 8 hrly for ≥4-6 weeks. Complicated intra-abdominal infections 500 mg orally or 400 mg IV 12 hrly for 7-14 days. Infectious diarrhea, mild/moderate/severe 500 mg orally 12 hrly for 5-7 days. Typhoid fever, mild/moderate 500 mg orally 12 hrly for 10 days. Uncomplicated urethral & cervical gonococcal infections 250 mg orally as a single dose. Empirical therapy in severe febrile neutropenic patients 400 mg IV 8 hrly in combination w/ piperacillin 50 mg/kg 4 hrly for 7-14 days. Max: 24 g/day. Inhalational anthrax (post-exposure) 500 mg orally or 400 mg IV 12 hrly for 60 days. Childn Complicated UTI or pyelonephritis (patients 1-17 yr) 10-20 mg/kg (max: 750 mg/dose) orally 12 hrly or 6-10 mg/kg (max: 400 mg/dose) IV 8 hrly for 10-21 days. Inhalational anthrax (post-exposure) 15 mg/kg (max: 500 mg/dose) orally or 10 mg/kg (max: 400 mg/dose) IV 12 hrly for 60 days.
Overdosage
View Ciproxin overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to ciprofloxacin or other quinolones. Childn, adolescents (<18 yr). Pregnancy & lactation.
Warnings
View Ciproxin warning for additional cautionary notes to warn of the potential risk of using the medicine.
Special Precautions
Known or suspected CNS disorders which may predispose to seizures or lower seizure threshold, tendonitis or tendon rupture. Maintain adequate hydration. Avoid excessive sunlight or artificial UV light. Renal impairment. May impair ability to drive or operate machinery.
Adverse Drug Reactions
Nausea, diarrhea, abnormal liver function tests, vomiting, rash. IV CNS disturbance, local inj site reactions, eosinophilia, headache, restlessness.
View ADR Monitoring Form
Drug Interactions
Theophylline, caffeine, cyclosporine, phenytoin, glyburide, warfarin or its derivatives, probenecid, methotrexate, NSAIDs. Mg- & Al-containing antacids, sucralfate, didanosine, products containing Ca, Fe or Zn.
View more drug interactions with Ciproxin
Pregnancy Category (US FDA)
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Caution For Usage
View Ciproxin caution for caution against possible variation of physical aspect of medicine.
Storage
View Ciproxin storage conditions for details to ensure optimal shelf-life.
Description
View Ciproxin description for details of the chemical structure and excipients (inactive components).
Mechanism of Action
View Ciproxin mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Quinolones
ATC Classification
J01MA02 - Ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Poison Schedule
P1S1S3
Presentation/Packing
FormPacking/PricePhoto
Ciproxin film-coated tablet
Ciproxin 250 mg x 100's ($1095)Ciproxin film-coated tab_633.gif White Round
Ciproxin 500 mg x 100's ($2090)Ciproxin film-coated tab_1381.gif White Oblong
Ciproxin infusion
Ciproxin 200 mg/100 mL x 1's ($350)
Ciproxin 400 mg/200 mL x 1's ($600)

Manufacturer:Bayer
Distributor:Zuellig
Click for Company's details

Related Ciproxin infusion information:
Drugs interacting with Ciproxin
Ciproxin Patient Med Info
Find Ciproxin in other countries
Search Ciproxin in Google
Search Ciproxin in PubMed
Abbreviation Index
  
 
China MIMS Online Home Page Hong Kong MIMS Online Home Page India MIMS Online Home Page Indonesia MIMS Online Home Page Malaysia MIMS Online Home Page Philippines MIMS Online Home Page Singapore MIMS Online Home Page Taiwan MIMS Online Home Page Thailand MIMS Online Home Page Vietnam MIMS Online Home Page